Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
Public ClinicalTrials.gov record NCT03642132. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100)
Study identification
- NCT ID
- NCT03642132
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Interventions
- Chemotherapy + avelumab followed by avelumab + talazoparib Drug
- Chemotherapy followed by talazoparib maintenance Drug
- Chemotherapy + bevacizumab followed by bevacizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 18, 2018
- Primary completion
- Dec 21, 2021
- Completion
- Dec 21, 2021
- Last update posted
- Apr 5, 2023
2018 – 2021
United States locations
- U.S. sites
- 46
- U.S. states
- 10
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - HAL | Phoenix | Arizona | 85016 | — |
| Arizona Oncology Associates, PC - HAL | Phoenix | Arizona | 85027 | — |
| Arizona Oncology Associates, PC - HAL | Scottsdale | Arizona | 85258 | — |
| Arizona Oncology Associates, PC - HAL | Tempe | Arizona | 85284 | — |
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85704 | — |
| Arizona Oncology Associates, PC - HOPE | Tucson | Arizona | 85711 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Sansum Clinic | Solvang | California | 93463 | — |
| Smilow Cancer Hospital at Yale-New Haven | New Haven | Connecticut | 06510 | — |
| NYU Winthrop Hospital, Gynecologic Oncology | Mineola | New York | 11501 | — |
| NYU Winthrop Hospital, Infusion Center | Mineola | New York | 11501 | — |
| NYU Winthrop Radiology | Mineola | New York | 11501 | — |
| Montefiore Medical Center - EPC | The Bronx | New York | 10461 | — |
| Montefiore Medical Center, Department of Obstetrics and Gynecology and Women's Health | The Bronx | New York | 10461 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Montefiore Medical Center-Centennial Facility | The Bronx | New York | 10467 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45211 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45230 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45236 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Northwest Cancer Specialists, P.C. | Portland | Oregon | 97213-2982 | — |
| Northwest Cancer Specialists, P.C. | Portland | Oregon | 97225 | — |
| Northwest Cancer Specialists, P.C. | Portland | Oregon | 97227 | — |
| Northwest Cancer Specialists, P.C. | Tualatin | Oregon | 97062 | — |
| Tennessee Oncology, PLLC | Dickson | Tennessee | 37055 | — |
| Tennessee Oncology, PLLC | Franklin | Tennessee | 37067 | — |
| Tennessee Oncology, PLLC | Gallatin | Tennessee | 37066 | — |
| Tennessee Oncology, PLLC | Hermitage | Tennessee | 37076 | — |
| Tennessee Oncology, PLLC | Lebanon | Tennessee | 37090 | — |
| Tennessee Oncology, PLLC | Murfreesboro | Tennessee | 37129 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37205 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37207 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37211 | — |
| Tennessee Oncology, PLLC | Shelbyville | Tennessee | 37160 | — |
| Tennessee Oncology, PLLC | Smyrna | Tennessee | 37167 | — |
| Texas Oncology Bedford | Bedford | Texas | 76022 | — |
| Texas Oncology | Fort Worth | Texas | 76104 | — |
| US Oncology Investigational Products Center (IPC) | Irving | Texas | 75063 | — |
| US Oncology Investigational Products Center | Irving | Texas | 75063 | — |
| Texas Oncology- San Antonio | San Antonio | Texas | 78240 | — |
| Virginia Oncology Associates | Chesapeake | Virginia | 23320 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Virginia Oncology Associates | Virginia Beach | Virginia | 23456 | — |
| Northwest Cancer Specialists, P.C. | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03642132, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03642132 live on ClinicalTrials.gov.